Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dexketoprofen trometamol + pethidine hydrochloride is a combination analgesic formulation containing two active ingredients with distinct mechanisms of action. Dexketoprofen trometamol is the tromethamine salt of dexketoprofen, a nonsteroidal anti-inflammatory drug (NSAID) that acts as a non-selective cyclooxygenase (COX-1 and COX-2) inhibitor, reducing prostaglandin synthesis to provide anti-inflammatory and analgesic effects[10][6]. Pethidine hydrochloride (also known as meperidine) is an opioid analgesic that acts primarily as an agonist at the mu-opioid receptor in the central nervous system, producing potent pain relief and sedation[2][5][1]. The combination aims to provide multimodal pain control by targeting both inflammatory and nociceptive pathways. This approach may offer synergistic or additive analgesia for moderate to severe acute pain, such as postoperative or procedural pain[6][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on dexketoprofen trometamol + pethidine hydrochloride.